

## CONTACTS

**Prof Maria Paola Costi, Action Chair,**  
*[mariapaola.costi@unimore.it](mailto:mariapaola.costi@unimore.it)*

**Prof Anabela Cordeiro da Silva, Action Vice Chair,**  
*[cordeiro@ff.up.pt](mailto:cordeiro@ff.up.pt)*

**Dr Lucia Sforzi, Science Officer,**  
*[lucia.forzi@cost.eu](mailto:lucia.forzi@cost.eu)*

**Prof Maria Laura Bolognesi, Expert for Stakeholder,**  
*[marialaura.bolognesi@unibo.it](mailto:marialaura.bolognesi@unibo.it)*

**Dr Paul Selzer, Expert of the industrial sector,**  
*[paul.selzer@novartis.com](mailto:paul.selzer@novartis.com)*

**Dr Chiara Borsari, Science Communication Coordinator,**  
*[chiara.borsari@unimi.it](mailto:chiara.borsari@unimi.it)*

**Ms Nathalie Warengnien, Administrative Officer,**  
*[Nathalie.Warengnien@cost.eu](mailto:Nathalie.Warengnien@cost.eu)*

## SOCIAL MEDIA

### Official Website:

[www.onehealthdrugs.com](http://www.onehealthdrugs.com)

### European Commission Website:

<https://www.cost.eu/actions/CA21111>

### LinkedIn page:

OneHealthdrugs COST Action – CA21111


### Twitter:

[@1Healthdrugs\\_ca](https://twitter.com/1Healthdrugs_ca)



## How can I participate?


Read the Project Description at  
<https://www.cost.eu/actions/CA21111/> →  
Inform the Main Proposer/Chair of  
your interest by email →  
Apply to join your WG of interest



# One Health Drugs against parasitic vector borne diseases in Europe and beyond

## #OneHealthdrugs

*Providing life-saving drugs to address  
high unmet medical needs while  
safeguarding our environment*



## For young researchers and innovators

For more details  
contact your leader

**Dr. Elisa Uliassi**  
[elisa.uliassi3@unibo.it](mailto:elisa.uliassi3@unibo.it)



## OUR MISSION

**COST Action CA21111 - OneHealthdrugs** “One Health drugs against parasitic vector borne diseases in Europe and beyond” (<https://www.cost.eu/actions/CA21111/>) is a consortium of researchers dedicated to improving drug development for Vector Borne Parasitic Diseases (VBPD) of humans and animals, through coordination of the **discovery of drugs that help control human and veterinary VBPD, adhering to the principles of the optimal profile for all organisms, while reducing the environmental impact of their associated research and the resulting new treatments.**

## YOUNG RESEARCHER INNOVATORS (YRI) HORIZONTAL GROUP (HG) 4

HG4 is composed by 97 YRI (< 40 years). HG4 aims to stimulate YRI research, training and networking activities across all areas of VBPD, by creating new knowledge and technologies according to the *OneHealth* goals. **HG4 is also committed to raise awareness and to make VBD research more environment-conscious.** To join us, please contact [elisa.uliassi3@unibo.it](mailto:elisa.uliassi3@unibo.it) or [clara.lima@i3s.up.pt](mailto:clara.lima@i3s.up.pt)

### WHO

53 countries, of which  
20 ITC 273 members  
Chair **Prof. MP Costi (IT)**  
Vice-Chair **Prof. A. Cordeiro-da-Silva (PT)**

### WHY

There is an urgent need to stop VBPD in both human and veterinary settings according to the One Health Principles

### WHAT

WG1-6 and HG1-7 activities cover VBPD drug discovery research, ecotoxicology aspects, dissemination and communication

### HOW

CA21111 and HG4 include a wide range of activities and opportunities. Some of them are exclusively dedicated to YRI!!



### Short-term Scientific Missions (STSMs):

STSMs are interlaboratory exchange visits on OHD topics and particularly intended for YRIs. These aim at strengthening the existing COST Actions by allowing scientists to go to an institution or laboratory in another COST country to foster collaboration, to learn a new technique or to use/apply instruments and/or methods not available in their own institution/laboratory. The STSM should last up to 6 months and shall be made within the time frame of the operation identified in the proposal and within the period of the respective Action. The financial support offer is a contribution to the overall expenses during the STSM (cover travel and subsistence expenses and is paid as a grant). The next grant application period starts in **October 2024** and all STSMs must be completed by **August 31, 2025**.

[www.onehealthdrugs.com](http://www.onehealthdrugs.com)

## OHD Marathon:

CA21111 OneHealthDrugs organizes every the **OHD Marathon in November to celebrate the One Health Day** – an international event established by the One Health Commission (<https://www.onehealthcommission.org>) - with **3-days of non-stop OHD presentations** and **a session dedicated to YRI and along with a YRI award for the best presentations!**



### OHD surveys:



CA21111 OneHealthDrugs is implementing several survey investigating different OHD topics: *WG1 Compound Databases Survey*, *WG6-HG4 survey on One Health and sustainability principles integration into PVBD drug discovery and development* <https://www.onehealthdrugs.com/working-area/surveys/compound-databases-survey/>

### Women in STEM initiative:

CA21111 OneHealthDrugs celebrates the International Day of Women and Girls in Science with dedicated activities: a collection of interviews to OHD women scientists is available at



<https://www.onehealthdrugs.com/women-in-stem/women-in-stem-onehealthdrugs-cost-action/> and a YOUTUBE video <https://www.youtube.com/watch?v=ZM8QZTP-fDE>



### Conference and ITC Conference Grants:

These grants are aimed at enhancing research collaboration where ideas and YRIs and PhD students from Inclusive Target Countries (ITC) can grow without borders by helping individuals to attend beneficial international conferences that are **not organized by COST Actions**. YRI who is affiliated with an institution located in an ITC country participating in the OHD can submit an application request for an ITC Conference Grant and must deliver an oral presentation at the conference. The application must be submitted at least 45 days before the conference start date. The next grant application period starts in **October 2024**.

### Training Schools:

CA21111 OneHealthDrugs organizes two Training Schools per year aimed at training YRI on OHD topics. **The next Training School will be on Cell culture as in vitro models for VBPD drugs, 25-27 Sept 2024, Poland.**



## Stay Tuned! Next events, WG-HG meetings and workshops:

CA21111 OneHealthDrugs organizes several on-line and in-presence WG-HG meetings and workshops related to different topics. Check all scheduled OHD events in 2024 at <https://www.onehealthdrugs.com/events/calendar-of-onehealthdrugs-events-year-2-2024>

**Next in-person event: *Advancements in Structural and Functional Drug Discovery of VBPD*. 3-5 July 2024 Oxford**

### Special Issue One Health and VBPD in ACS Infectious Diseases:

ACS Infectious Diseases

This Special Issue will highlight the development of drugs against human and animal vector-borne parasitic disease (VBPD) using innovative technologies with minimal environmental risks. See the Editorial by Profs Costi & Cordeiro-da-Silva

<https://pubs.acs.org/doi/10.1021/acsinfecdis.3c00304>



**OHD newsletter:** containing news concerning all OHD activities, past and future events and dissemination outputs